Evidence map›Paper›PMID 37024699›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Drug Target Elucidation Through Isolation and Analysis of Drug-Resistant Mutants in Cryptococcus neoformans.

Michael J Hoy, Joseph Heitman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michael J HoyDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, USA.
Joseph HeitmanDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, USA. heitm001@duke.edu.

Funding

Structure, function, and evolution of the Cryptococcus MAT locusR01AI050113 · NIAID · DUKE UNIVERSITY · PI HEITMAN, JOSEPH · 2002 to 2024
$8.5M
ROLE OF CALCINEURIN IN C. NEOFORMANS MATING AND FRUITINGR01AI039115 · NIAID · DUKE UNIVERSITY · PI HEITMAN, JOSEPH · 1997 to 2025
$6.7M
Genetics of Cryptococcus sexual reproductionR37AI039115 · NIAID · DUKE UNIVERSITY · PI HEITMAN, JOSEPH · 2011 to 2020
$4.9M
Structural Biological Development of Fungal-Specific Calcineurin InhibitorsR56AI112595 · NIAID · DUKE UNIVERSITY · PI HEITMAN, JOSEPH, HONG, JIYONG · 2020 to 2020
$669k
Structure-guided development of fungal specific calcineurin inhibitorsF31AI150120 · NIAID · DUKE UNIVERSITY · PI HOY, MICHAEL · 2020 to 2021
$76k
NIAID NIH HHS F31 AI150120NIAID NIH HHS R01 AI039115NIAID NIH HHS R01 AI050113NIAID NIH HHS R37 AI039115NIAID NIH HHS R56 AI112595
6 · The paper itself

Abstract

Drug target identification is an essential component to antifungal drug development. Many methods, including large chemical library screening, natural product screening, and drug repurposing efforts, can identify compounds with favorable in vitro antifungal activity. However, these approaches will often identify compounds with no known mechanism of action. Herein, we describe a method utilizing the human fungal pathogen Cryptococcus neoformans to identify antifungal drug targets through the isolation of spontaneous resistant mutants, antifungal testing, whole-genome sequencing, and variant analysis.

Indexed as

CryptococcosisCryptococcus neoformansAntifungal AgentsHumansAntifungal AgentsAntifungalMechanism of actionSNP callingSpontaneous mutantsTherapeutic targetVariant identificationWhole-genome sequencing

Identifiers

PMID37024699
PMCPMC10602406

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.